HC Wainwright Brokers Decrease Earnings Estimates for COGT

Key Points

• HC Wainwright lowered Cogent Biosciences’ Q3 2026 EPS estimate to a loss of $0.59 per share from $0.56, while maintaining a Buy rating and a $55 price target. The firm forecasts losses of $0.62 per share in Q4 and $2.37 for full-year 2026.
• Cogent’s latest quarterly loss of $0.52 per share was better than analysts’ expected loss of $0.55. Despite mixed analyst views, the stock has a consensus “Moderate Buy” rating and a $49.40 average price target.
• Shares opened down 4.2% at $35.31, below their 50-day moving average of $38.42, although the company reported strong liquidity with a 13.57 quick ratio and current ratio.

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Investment analysts at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for Cogent Biosciences in a note issued to investors on Wednesday, August 19th. HC Wainwright analyst R. Burns now expects that the technology company will post earnings per share of ($0.59) for the quarter, down from their prior estimate of ($0.56). HC Wainwright currently has a "Buy" rating and a $55.00 target price on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Cogent Biosciences' Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.37) EPS.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.03.

A number of other brokerages have also commented on COGT. Piper Sandler lifted their price target on shares of Cogent Biosciences from $52.00 to $55.00 and gave the stock an "overweight" rating in a report on Monday. Wedbush reaffirmed an "outperform" rating and set a $55.00 target price on shares of Cogent Biosciences in a research report on Friday, May 29th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cogent Biosciences in a report on Wednesday, July 8th. Finally, Guggenheim upped their price target on Cogent Biosciences from $45.00 to $52.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $49.40.

Cogent Biosciences Trading Down 4.2%

Shares of NASDAQ COGT opened at $35.31 on Friday. The firm has a 50 day moving average price of $38.42 and a two-hundred day moving average price of $36.63. The stock has a market cap of $6.13 billion, a P/E ratio of -16.35 and a beta of 0.38. Cogent Biosciences has a 52-week low of $11.60 and a 52-week high of $43.73. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.57 and a current ratio of 13.57.

Hedge Funds Weigh In On Cogent Biosciences

A number of hedge funds have recently bought and sold shares of the company. J.Safra Asset Management Corp bought a new stake in Cogent Biosciences during the second quarter valued at $27,000. EverSource Wealth Advisors LLC lifted its stake in shares of Cogent Biosciences by 1,164.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company's stock valued at $25,000 after purchasing an additional 652 shares during the period. Parallel Advisors LLC acquired a new position in shares of Cogent Biosciences in the 1st quarter valued at about $39,000. Global Retirement Partners LLC bought a new stake in shares of Cogent Biosciences during the 4th quarter valued at about $37,000. Finally, Summit Securities Group LLC acquired a new stake in Cogent Biosciences during the first quarter worth approximately $46,000.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source